Understand the source comparison
Fertility Peptides 2026 Update: Comparison of Clinical Compounds
Kisspeptin-54 Triggers GnRH pulse → LH surge for ovulation IVF ovulation trigger (replaces hCG in high responders) 80% reduction (0.8% vs 4.2% with hCG) Phase 3 complete, FDA Fast Track designation Gold standard for OHSS prevention in controlled ovarian stimul
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin-54
- Triggers GnRH pulse → LH surge for ovulation
- IVF ovulation trigger (replaces hCG in high responders)
- 80% reduction (0.8% vs 4.2% with hCG)
- Phase 3 complete, FDA Fast Track designation
- Gold standard for OHSS prevention in controlled ovarian stimulation. Mechanism is cleaner than any hCG alternative
- Cetrorelix (GnRH antagonist)
- Blocks pituitary GnRH receptors, prevents premature LH surge
- Controlled ovarian stimulation timing control
- Neutral (prevents OHSS by design, not a trigger)
- FDA-approved (2000), refined 2026 protocols
- Essential tool in modern IVF. 2026 refinement is dosing precision, not mechanism change
- AMH-R2-antagonist-701
- Blocks AMH type-2 receptors on granulosa cells, restores FSH sensitivity
- PCOS ovulation induction (anovulatory cycles)
- Not applicable (different patient population)
- Phase 2 (58% ovulation rate in trial cohort)
- Promising but early. Requires Phase 3 confirmation before replacing letrozole as PCOS first-line
- Degarelix (GnRH antagonist, extended)
- Suppresses gonadotropins for 28 days per injection
- Endometriosis suppression, fertility preservation pre-chemotherapy
- Not applicable (suppression protocol, not stimulation)
- FDA-approved (oncology), off-label fertility use expanding
- Niche but valuable. Sustained suppression without daily injections benefits specific cases